Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer

NCT ID: NCT06555588Sponsor: Duke UniversityLast updated: 2026-03-16

Summary

The goal of this clinical trial is to test the efficacy a new psychosocial symptom management intervention called ENGAGE for patients with Stage IV breast, prostate, lung, or colorectal cancer. Participants will be randomized to ENGAGE or a Supportive Care intervention. Patient-reported outcomes will be assessed at baseline, 2 months, and 4 months.

Detailed description

Pain, fatigue, and distress are highly prevalent, co-occurring, and interfering symptoms in patients with advanced cancer. This trial will test a brief telehealth delivered psychosocial intervention called ENGAGE. ENGAGE aims to help patients decrease symptom interference and improve their quality of life. Patients with Stage IV cancer (breast, prostate, lung, or colorectal) and moderate-to-severe symptom interference will be randomized to ENGAGE or Supportive Care. Patient-reported outcomes will be assessed at baseline, 2 months, and 4 months. Aim 1 is to determine ENGAGE's efficacy for reducing symptom interference (primary outcome) at 2 months (primary endpoint). Aim 2 is to determine ENGAGE's efficacy for improving secondary outcomes at 2 months. Aim 3 is to test the maintenance of ENGAGE's effects on primary and secondary outcomes at 4 months. An exploratory aim seeks insights for future implementation efforts using mixed-methods data collection from patients, oncology providers, and clinic leaders.

Arms & interventions

  • BehavioralENGAGE

    This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.

  • BehavioralSupportive Care

    This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).

Outcome measures

Primary

  • MD Anderson Symptom Inventory (MDASI) Interference with Daily Living Scale

    This measure assesses the degree to which, over the past 7 days, symptoms of pain, fatigue, and/or distress have interfered with patients' general activity, mood, work (including work around the house), relations with other people, walking, and enjoyment of life. Items are scored from 0 = "Did not interfere" to 10 = "Interfered completely," and averaged for a composite score.

    Time frame: 2 months

Secondary

  • MD Anderson Symptom Inventory (MDASI) Interference with Daily Living Scale

    Time frame: 4 months

  • MD Anderson Symptom Inventory (MDASI) Symptom Severity Scale

    Time frame: 2 months and 4 months

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Symptoms

    Time frame: 2 months and 4 months

  • Openness to Experience subscale of the Comprehensive Assessment of Acceptance and Commitment Therapy (CompACT)

    Time frame: 2 months and 4 months

  • Behavioral Awareness subscale of the Comprehensive Assessment of Acceptance and Commitment Therapy (CompACT)

    Time frame: 2 months and 4 months

  • Valued Action subscale of the Comprehensive Assessment of Acceptance and Commitment Therapy (CompACT)

    Time frame: 2 months and 4 months

  • Brief Pain Inventory (BPI)

    Time frame: 2 months and 4 months

  • Brief Fatigue Inventory (BFI)

    Time frame: 2 months and 4 months

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety-Short Form

    Time frame: 2 months and 4 months

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Depression-Short Form

    Time frame: 2 months and 4 months

  • Functional Assessment of Cancer Therapy-General (FACT-G)

    Time frame: 2 months and 4 months

  • Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp)

    Time frame: 2 months and 4 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Receiving cancer care at 1) a Duke Cancer Network (DCN) clinic; or 2) the Duke Cancer Institute (DCI) and live in a rural county at least 60 miles from Duke * Oncologist confirmed Stage IV breast, prostate, lung, or colorectal cancer * Worst pain, fatigue, or distress rated at \>/= 3 out of 10 in the past 7 days for at least 2 symptoms * MD Anderson Symptom Inventory (MDASI) Interference with Daily Living Scale average score of \>/= 3 out of 10 in the past 7 days * Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower * At least 18 years old * Ability to speak and read English * Hearing and vision that allows for successful completion of telehealth sessions Exclusion Criteria: * Significant cognitive impairment indicated in medical chart or during telephone screening on a mental status questionnaire * Serious psychiatric condition (e.g., schizophrenia, suicidal intent) that would contraindicate safe study participation * Participation in the last 6 months in Cognitive-Behavioral Therapy or Acceptance and Commitment Therapy for cancer symptom management * Enrollment in hospice at screening

Study locations (1)

Duke Cancer Network

Durham, North Carolina, 27713

Recruiting
Joseph G Winger, PhD · Contact

References

  • Winger JG, Kelleher SA, Yu JA, Ma JE, Majestic CM, Martinson EB, Olsen MK, Lerebours R, Sutton LM, Somers TJ. Engage: Protocol of a randomized controlled trial of a telehealth-delivered psychosocial intervention to decrease symptom interference in patients with advanced cancer. Contemp Clin Trials. 2025 Sep;156:108053. doi: 10.1016/j.cct.2025.108053. Epub 2025 Aug 18.(PubMed)